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Abstract
Acquisition of iron from host complexes is mediated by four surface-located receptors of
Neisseria meningitidis. The HmbR protein and heterodimeric HpuAB complex bind to hae-
moglobin whilst TbpBA and LbpBA bind iron-loaded transferrin and lactoferrin complexes,
respectively. The haemoglobin receptors are unevenly distributed; disease-causing menin-
gococcal isolates encode HmbR or both receptors while strains with only HpuAB are rarely-
associated with disease. Both these receptors are subject to phase variation and 70–90%
of disease isolates have one or both of these receptors in an ON expression state. The sur-
face-expression, ubiquity and association with disease indicate that these receptors could
be potential virulence factors and vaccine targets. To test for a requirement during disease,
an hmbR deletion mutant was constructed in a strain (MC58) lacking HpuAB and in both a
wild-type and TbpBA deletion background. The hmbRmutant exhibited an identical growth
pattern to wild-type in whole blood from healthy human donors whereas growth of the
tbpBAmutant was impaired. These results suggest that transferrin is the major source of
iron for N.meningitidis during replication in healthy human blood. To examine immune
responses, polyclonal antisera were raised against His-tagged purified-recombinant variants
of HmbR, HpuA and HpuB in mice using monolipopolysaccharide as an adjuvant. Addition-
ally, monoclonal antibodies were raised against outer membrane loops of HmbR presented
on the surface of EspA, an E. coli fimbrial protein. All antisera exhibited specific reactivity in
Western blots but HmbR and HpuA polyclonal sera were reactive against intact meningococ-
cal cells. None of the sera exhibited bactericidal activity against iron-induced wild-type menin-
gococci. These findings suggest that the HmbR protein is not required during the early stages
of disease and that immune responses against these receptors may not be protective.
PLOS ONE | DOI:10.1371/journal.pone.0133855 July 24, 2015 1 / 22
OPEN ACCESS
Citation: Bidmos FA, Chan H, Praekelt U, Tauseef I,
Ali YM, Kaczmarski EB, et al. (2015) Investigation
into the Antigenic Properties and Contributions to
Growth in Blood of the Meningococcal Haemoglobin
Receptors, HpuAB and HmbR. PLoS ONE 10(7):
e0133855. doi:10.1371/journal.pone.0133855
Editor: Yung-Fu Chang, Cornell University, UNITED
STATES
Received: March 13, 2015
Accepted: July 3, 2015
Published: July 24, 2015
Copyright: © 2015 Bidmos et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was funded by the Meningitis
Research Foundation (http://www.meningitis.org/).
Grant number 1002.0 entitled “Examination of
meningococcal haemoglobin receptors as potential
vaccine targets” was awarded to HC, EK, IF, and
CDB. The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Introduction
Neisseria meningitidis (Nm) is a frequent coloniser of the human oropharynx [1, 2] but is also
a prolific pathogen. During a 15-year period (1996–2010), cyclic epidemics in the African men-
ingitis belt affected 800,000 individuals with 30% having fatal outcomes or neurological
sequelae (WHO, 2011). A significantly lower disease burden is reported in other parts of the
world; however, localised epidemics occur with morbidity rates ranging from 0.28 cases per
100,000 in the United States to 2.4 cases per 100,000 in New Zealand [3]. Polysaccharide conju-
gate vaccines of different valences have been effective in preventing disease caused by strains of
serogroups A, C, W and Y. Due to the potential for autoimmunity with a serogroup B polysac-
charide-based vaccine [4], only epidemic-specific outer membrane vesicles were employed for
controlling meningococcal disease of serogroup B aetiology [5–7]. Recently a novel recombi-
nant protein-based vaccine, 4CMenB (also known as Bexsero) has been developed and licensed
for prevention of MenB disease. This vaccine is predicted to provide protection against 70–
90% of the meningococcal strains currently circulating in Europe [8, 9]. One aim of current
meningococcal vaccine research is to extend coverage to additional strains by inclusion of addi-
tional vaccine antigens in a multi-component vaccine.
Nm possesses a myriad of nutrient scavenging and immune evasion systems. Iron is abun-
dant in the human host but is rarely freely available with 30% and 66% of total body iron being
complexed to ferritin or haemoglobin (Hb), respectively [10]. Iron-binding proteins such as
lactoferrin [11], transferrin [12] and hepcidin [13] are involved in the sequestration of free
extracellular iron, thereby creating an iron-limited environment in the human host. Some of
these iron-binding proteins are implicated in nutritional immunity and a hypoferremic
response during the early stages of infection [14]. Iron complexed to lactoferrin and transferrin
serve as valuable iron sources for meningococci and are utilised via the bipartite LbpBA and
TbpBA systems, respectively [15]. Each system is composed of a substrate-binding lipoprotein
(LbpB and TbpB) and a transmembrane pore-forming protein (LbpA and TbpA). Expression
of both systems is transcriptionally regulated by Fur and up-regulated in human whole blood
[16], indicating the importance of these iron uptake systems to the meningococcus. Unsurpris-
ingly, given the abundance of Hb in the human host, Nm can also acquire iron from Hb and
Hb-complexes via two receptors, HpuAB and HmbR.
The HpuAB receptor is encoded by two co-transcribed genes, hpuA and hpuB, and is a
bipartite receptor consisting of HpuA, a surface-exposed lipoprotein, and HpuB, a transmem-
brane protein [17]. HpuAB can bind both Hb and haemoglobin-haptoglobin (Hb-Hp) com-
plexes [17] releasing haem which is then transported into the cell [18]. However, utilisation of
free haem by gonococci is neither HpuAB nor TonB-dependent [19]. Expression of hpuAB is
transcriptionally-regulated by Fur [17] and translationally-controlled by a polyG tract in the
reading frame of hpuA [20]. HpuA cannot mediate Hb or Hb-Hp utilisation independently of
HpuB but experimental data suggests that it contributes significantly to optimal binding of
HpuAB to Hb and Hb-Hp. Conversely HpuB can mediate Hb utilisation in the absence of
HpuA, albeit at levels lower than the functional HpuAB receptor [21–23]. The second Hb
receptor, HmbR, is a TonB-dependent receptor of molecular mass ~89 kDa [24]. Expression of
hmbR is phase-variable via a polyG tract within the reading frame [20, 25] and down-regulated
under iron-replete conditions. Several isotypes of the Hb receptors exist with antigenic varia-
tion in HmbR being primarily determined by sequences of three putative surface-exposed
loops [26–28].
The importance of these Hb receptors to meningococcal virulence has been demonstrated
in an infant rat model where proliferation of a ΔhmbRmutant was attenuated [29] and in an
accidental human passage that revealed a difference in the hpuAB expression status of the
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inoculum (hpu-OFF) and output (hpu-ON) populations [30]. These experimental data coupled
with genetic studies that reported a bias for the presence and PV-ON status of one or both genes
(hpuAB and hmbR) in disease isolates present strong indications that Hb-utilisation is crucial to
meningococcal virulence [27, 31, 32]. While the constitutively-expressed meningococcal Tf
receptor, TbpBA, has been established as an important virulence factor in Nm [33], the impor-
tance of the phase-variable Hb-acquisition systems, to survival and growth of the meningococcus
in human whole blood is yet to be elucidated. Using an ex vivo human whole blood model,
we examined the ability of phase-OFF variants of hmbR and hpuAB (or their equivalent i. e.
mutants) to cause disease by proliferating in human blood. To ascertain the suitability of includ-
ing these receptors in future vaccine preparations, we assessed the bactericidal property of serum
antibodies generated in mice against purified recombinant HpuA, HpuB and HmbR.
Materials and Methods
Ethics statement
Studies with human blood samples were approved by the Leicester Research Ethics Committee.
All volunteers provided written consent on a form approved by the ethics committee. Experi-
ments with animals were approved by the NIBSC Ethics Committee and performed under
home license PPL No. 80/2157) in accordance with the animal (scientific procedures) act 1986.
Every effort was taken to minimize suffering. Anaesthesia without recovery was used to sacri-
fice animals.
Bacterial strains
A list of Nm strains used in this study is presented in Table 1. Meningococcal carriage strains
were obtained from a study conducted from November 2008 to June 2009 at the University of
Nottingham [2]. Disease isolates, MC58 (B:P1.7,16–2:F1-5:CC-32), 8047 (B:P1.5–1,2–2:F3-6:
ST-8) and H44/76 (B:P1.7,16:F3-3:CC-32) were isolated from meningococcal disease patients
in the UK [34], US [35] and Norway [36], respectively. All strains were routinely grown in a
humidified incubator at 37°C and 5% CO2 on Brain Heart Infusion (BHI), supplemented with
Levinthal’s, or Mueller-Hinton (MH) media. Antibiotics were added to media, as required. E.
coli strains DH5α and BL21 (DE3) were routinely grown in Luria agar or broth (LB) (Oxoid)
supplemented with antibiotics, as required, at 37°C under aerobic conditions. For blue-white
screening, an X-gal-IPTG mixture (10 mg/ml; Melford) was added to media at a working con-
centration of 10 μg/ml.
Induction of iron-regulated gene expression
Overnight liquid cultures, grown without iron-restriction, were diluted 20-fold into fresh
media and incubated until the OD600 was ~0.5. Desferal (EMD Chemicals Inc.) was then added
at a final concentration of 30 μM and the culture was incubated for a further 3 hours.
Plasma and serum samples
Whole human blood was collected by qualified phlebotomists from healthy subjects in either
sterile heparin-coated vacutainers for plasma or EDTA-coated vacutainers for sera (BD Vacu-
tainer Systems, UK). For the preparation of sera, whole blood samples were coagulated on ice
for 7 hours. A centrifugation step of 4000 rpm at 4°C for 10 minutes was used to separate
serum from cellular material. Similarly, plasma was obtained from non-coagulated blood via
centrifugation (4000 rpm at 4°C for 10 minutes).
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Construction of hmbR, hpuAB, and tbpBA deletion plasmids
Primers, HmbR-Nterm and dhmbR-rev (Table 2), were used to amplify a 542 bp region from
the N-terminus of hmbR from strain MC58. Similarly, 676 bp from the C-terminus of hmbR
was amplified with primers HmbR-Cterm and dhmbR-for (Table 2). These amplicons con-
tained BamHI restriction sites, introduced via dhmbR-for and dhmbR-rev, which facilitated
downstream ligation and sub-cloning steps. The ~1.3 kb fragment that resulted from ligation
of both amplicons via the BamHI sites was cloned into the pGEM-T Easy plasmid vector,
according to manufacturer’s instructions (Promega) to create pFAB-7. A kanamycin resistance
cassette was excised from pUC4kan and inserted into the pFAB-7 via the BamHI site to give
pFAB-9.
For mutagenesis of hpuAB, the complete locus was amplified from strain 8047 with primers
HpuA-Nterm and HpuB-Cterm and cloned in the pGEM-T Easy plasmid vector. An inverse
PCR was performed on this plasmid with two primers, HA-Inv938 and HB-Inv1, with EcoRV
sites on their 5’ ends. This product deletes 120 bp form the 3’ end of HpuA and 1,500 bp from
the 5’ end of HpuB. PCR products were digested with EcoRV and then ligated with T4 DNA
Table 1. List of N.meningitidis strains.
Strain Source Description
MC58 disease B: P1.7,16–2: F1-5: CC-32 (hpuAB-, hmbR-ON)
MC58 ΔhmbR::kan this study hmbR deletion mutant of strain MC58
MC58 ΔtbpBA::ery this study tbpBA deletion mutant of strain MC58
MC58 ΔhmbR::kanΔtbpBA::ery this study hmbR and tbpBA deletion mutant of strain MC58
H44/76 disease B: P1.7,16: F3-3: CC-32 (hpuAB-, hmbR-ON)
N66.1 carriage B: P1.7–2,4: F1-5: CC-41/44 (hpuAB-, hmbR-ON)
N78.1 carriage E: P1.21–7,16: F-ND: CC-1157 (hpuAB-OFF, hmbR-OFF)
N121.1 carriage B: P1.22,14: F5-5: CC-213 (hpuAB-, hmbR-ON)
N123.1 carriage NG: P1.21–7,16: F-ND: CC-1157 (hpuAB-ON, hmbR-ON)
N132.1 carriage B: P1.22,14: F5-5: CC-213 (hpuAB-, hmbR-ON)
N176.1 carriage B: P1.19,15: F5-1: CC-32 (hpuAB-ON, hmbR-ON)
N182.1 carriage B: P1.12–6,13–4: F5-1: CC-32 (hpuAB-, hmbR-ON)
N193.1 carriage NG: P1.18,25: F-ND: ST-845 (hpuAB-OFF, hmbR-ON)
8047 disease B: P1.5–1,2–2: F3-6: ST-8 (hpuAB-ON, hmbR-OFF)
8047 ΔhmbR::kan this study hmbR deletion mutant of strain 8047
8047 ΔhpuAB::kan this study hpuAB deletion mutant of strain 8047
8047 ΔtbpBA::ery this study tbpBA deletion mutant of strain 8047
8047 ΔhmbR::kan ΔtbpBA::ery this study hmbR and tbpBA deletion mutant of strain 8047
8047 ΔhpuAB::kan ΔtbpBA::ery this study hpuAB and tbpBA deletion mutant of strain 8047
8047 ΔhmbR::ery ΔhpuAB::kan [37] hmbR and hpuAB deletion mutant of strain 8047
N88.1 carriage Y: P1.21,16: F3-7: CC-174 (hpuAB-OFF, hmbR-)
N272.1 carriage Y: P1.21,16: F3-7: CC-174 (hpuAB-ON, hmbR-)
N46.1 carriage Y: P1.21,16: F3-7: CC-174 (hpuAB-ON, hmbR-)
N52.1 carriage Y: P1.21,16: F3-7: CC-174 (hpuAB-ON, hmbR-)
N117.1 carriage Y: P1.5–1,10–1: F1-3: CC-167 (hpuAB-ON, hmbR-)
N119.1 carriage E: P1.5,2: F1-7: CC-60 (hpuAB-ON, hmbR-OFF)
N146.1 carriage H: P1.21,16: F4-1: ST-ND (hpuAB-ON, hmbR-ON)
N199.1 carriage B: P1.22,9: F5-5: CC-269 (hpuAB-ON, hmbR-OFF)
N222.1 carriage Y: P1.5, 10–1: F4-1: CC-23 (hpuAB-ON, hmbR-)
doi:10.1371/journal.pone.0133855.t001
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ligase prior to transformation into E. coli DH5α to create pGEMT-ΔhpuAB. A kanamycin cas-
sette was inserted into the EcoRV site to create pGEMT-ΔhpuAB-Kan.
A tbpBA deletion construct (pIT-ΔtbpBA) was kindly provided by Isfahan Tauseef [37]. For
the generation of double knockout strains, a different selectable marker for the deletion of
tbpBA in the single knockout strains was required as both ΔhmbR and ΔhpuABmutant strains
were kanamycin resistant. The kanamycin selectable marker in pIT-ΔtbpBA was, therefore,
replaced with an erythromycin resistance cassette flanked by one copy of the Neisserial DNA
uptake sequence (DUS) on either end to yield pFAB-22.
Natural transformation of Nm
Amodification of the transformation protocol described in [38] was employed in the present
study. Briefly, a 1:10 dilution of cells grown overnight in supplemented BHI medium was incu-
bated for one hour with shaking at 37°C. 200 μl of the culture was added to supplemented BHI
agar in 24-well plates. The culture was incubated for 5 hours at 37°C, 5% CO2 before 1.5 μg of
the NdeI-linearised plasmid was added. The transformation mixture was incubated overnight;
subsequently, cells were harvested and plated on selective BHI agar plates. Colonies present on
selective plates after 24 hours were confirmed as Nmmutants using specific PCR (amplifica-
tion of short regions of the ctrA and crgA genes and of the junction between the antibiotic cas-
sette and mutated gene) and disc diffusion assays.
Disc diffusion assay
Approximately 109 Nm cells were seeded on iron-chelated Mueller-Hinton (MH) agar. Sterile
filter discs (5 mm in diameter) infused with an iron source [500 μg of human holo-transferrin
(Sigma-Aldrich), 100 μg of ferrous-stabilised human haemoglobin A0 (Sigma-Aldrich) or 100
mM FeCl3] were carefully placed on different sections of the plate. Alternatively, 5 μl of the
exogenous iron sources were dropped on different sections of the plate. Sterile PBS buffer was
also included as a negative control. Plates were incubated overnight for 24 to 48 hours until
rings of growth were clearly visible around the iron sources.
Generation of polyclonal antisera in mice
For expression of recombinant HpuA, HpuB and HmbR proteins from strains N88.1, 8047 and
MC58 respectively, amplicons were generated with specific primers (Table 2) and cloned into a
pLEICS-03 vector (PROTEX laboratory, University of Leicester, UK). For hpuA, the N-termi-
nal primer was located immediately downstream of the repeat tract whilst for the other genes
the primer binding site started from the initiation codon. The hmbR gene was amplified from
isolates with an ON number of repeats and the constructs was confirmed to have retained an
in-frame repeat tract. Expression of recombinant protein was induced in transformed E. coli
BL21 (DE3) cultures at OD600 of ~ 0.5 with IPTG at a final concentration of 1 mM.
Recombinant HpuA was purified from the soluble fraction of BL21 cell lysates using a Ni-
Sepfast gravity column, as per manufacturer’s instructions (Flowgen Bioscience). Inclusion
bodies containing recombinant HpuB and HmbR were purified by cell lysis and washing in
50 mM TrisHCl pH 8. The inclusion bodies were then treated with solubilisation buffer
(20 mM Tris.Cl pH 8.0, 6M guanidine HCl, 1mM EDTA) and applied in a drop-wise manner
to nine volumes of refolding buffer (20 mM Tris.Cl pH 8.0, 5% v/v LDAO, 250mMNaCl,
50μMHemin) on a magnetic stirrer. The solubilised protein was allowed to refold for 4 hours
at room temperature and the resulting haem-bound proteins dialysed overnight at 4°C against
dialysis buffer (20 mM Tris.Cl pH 8.0, 0.1% v/v LDAO). The identity of recombinant proteins
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was confirmed using mass spectrometry (Protein and Nucleic Acid Chemistry Laboratory,
University of Leicester, UK).
Six groups of 10 female BALB/c mice (6–7 weeks old) were subcutaneously injected with
200 μl of antigen preparations (20 μg antigen + 10 μg monophosphoryl lipid A) as follows:-
r8047-HmbR (group 1); rMC58-HmbR (group 2); r8047-HpuA (group 3); rN88-HpuA (group
4); r8047-HpuB (group 5). The sixth group received no antigen (MPL only). Boosters, contain-
ing 200 μl of the antigen preparations as above, were administered at weeks 3 and 5. Terminal
bleeds were obtained at week 7.
Production of anti-HmbRmonoclonal antibodies
Epitopes corresponding to predicted surface-exposed loops 2 (HmbR193-229), 8 (HmbR550-577)
and 11 (HmbR739-750) of HmbR from strain MC58 were amplified with specific primers
(Table 2) and used to replace an immunogenic loop of the E. coli EspA protein. Three mice
were immunised with each of the antigen preparations while a fourth mouse received a combi-
nation of all three antigens. Test bleeds were first screened for presence of antibodies by ELISA
and probing of Western blots using recombinant EspA-HmbR and meningococcal lysates as
target antigens. Monoclonal antibodies were produced from immortalised spleen cells of mice
obtained after 7 weeks as described by Praekelt et al., [39]. Briefly, spleen cell-NS0 hybridomas
were generated and selected following screening of secreted antibodies by ELISA against
recombinant EspA-HmbR, purified His-tagged HmbR and meningococcal cell lysates. Positive
hybridomas were subsequently sub-cloned twice. Supernatants from these hybridomas were
stored at -20°C.
Western and colony immunoblotting
Cell lysates and protein samples were analysed on 10% SDS-PAGE gels. Electrophoresis was
performed at a constant voltage of 80 V for 3 hours. Electrophoresed samples were transferred
from SDS-PAGE gels onto pre-activated polyvinylidene fluoride (PVDF) membranes (Merck
Millipore) using ice-cold Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% metha-
nol). Transfer was done for 1 hour at constant ampere of 150 Amp before membranes were
blocked overnight at 4°C with blocking buffer (PBS, 0.5% Tween-20, 5%Milk). Following
blocking, membranes were incubated with an appropriate concentration of primary antibodies
in blocking buffer for 1 hour at room temperature with gentle shaking. Membranes were
washed thrice with wash buffer (PBS, 0.5% Tween-20) and subsequently incubated in a 1:2000
dilution of anti-mouse horseradish peroxidase (HRP), also prepared in blocking buffer, for
1 hour at room temperature. Membranes were washed thrice before signals were developed
with an EZ-ECL Chemiluminescence kit for HRP (Geneflow). Blots were quantified with Ima-
geJ software.
For assessment of protein surface expression with colony immunoblotting, ~ 109 Nm cells
were spotted on BHI agar plates supplemented with 10% Levinthal’s and 65 μM desferal. After
an overnight incubation, growth was transferred onto blotting membranes for 10 minutes.
Membranes were subsequently blocked with blocking buffer for 1 hour at room temperature.
Excess cellular material was gently removed from membranes before incubation with primary
antibodies (1:100 in blocking buffer) for 2 hours at room temperature. Unbound primary anti-
bodies were removed by washing membranes thrice with wash buffer. The wash step was
immediately followed by incubation with a 1:2000 dilution of an anti-mouse IgG HRP or alka-
line phosphatase conjugate antibody. After 1 hour, membranes were washed and signals devel-
oped using either an EZ-ECL kit (GeneFlow) or BCIP/NBT substrate solution (Perkin Elmer).
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Flow cytometry
Analysis of protein surface expression by flow cytometry was performed as described previ-
ously [40]. Briefly, 150 μl of cells, cultured in iron-replete or iron-restricted conditions, were
pelleted by centrifugation at 8,000 rpm for 1 minute in a microcentrifuge and washed twice
with assay buffer (50 mM Tris.Cl pH 7.5, 150 mMNaCl, 5 mM CaCl2, 0.05% Tween-20). Cells
were subsequently incubated with a 1:20 dilution of antigen-specific antibodies prepared in
150 μl assay buffer at room temperature for 1 hour after which unbound antibodies were
removed in three wash cycles. This was followed by addition of 20 μg/ml of the secondary
antibody, Alexa Fluor 488 Goat Anti-Mouse IgG (H+L) (Life Technologies), and incubation
for 1 hour at room temperature. Three wash cycles were performed before cells were inacti-
vated in 1 ml of fixer solution (0.05% formalin in PBS). Samples were analysed on a BD
FACSCalibur system.
Human whole blood growth assay
The protocol for the whole blood assay was adapted from previous studies [41, 42]. Blood sam-
ples were collected from mannose-binding lectin (MBL)-deficient or normal donors. MBL defi-
ciency has been linked with an increased susceptibility to meningococcal disease [43] and an
active MBL pathway can accelerate opsonophagocytosis of Nm by macrophages [44]. Thus,
whole blood samples from these volunteers were expected to be less inhibitory of meningococ-
cal survival and growth. A 1:20 dilution of an overnight Nm culture was used to inoculate MH
broth supplemented with 0.25% glucose and 20 μMCMP-N-acetylneuraminic acid sodium salt
(CMP-NANA) for exogenous sialylation of Nm LOS. Approximately 106 cells were taken from
mid-logarithmic phase cultures and used to inoculate 500 μl of freshly-collected heparinised
human blood (0.01 U of heparin/μl of blood) in 24-well plates. Blood cultures were incubated
at 37°C, 5% CO2 for 8 hours. CFU counts of Nm cells pre-inoculation into blood, immediately
after inoculation (T0) and at hourly intervals were taken. Doubling times were estimated using
Doubling Time software.
Human serum bactericidal assay (hSBA)
Amodified protocol was used to assess serum sensitivity of meningococcal strains and the bac-
tericidal activity of monoclonal and polyclonal antibodies. Liquid cultures were grown until an
OD600 of ~0.5 was reached. Where iron restriction conditions were required, 30 μM desferal
was added and grown for a further three hours to induce expression of iron-regulated genes.
Cultures were subsequently diluted to an OD600 of 0.1 in PBSB (PBS, 0.15 mM CaCl2, 0.5 mM
MgCl2). For the assay, the following components were transferred to specified wells of a
96-well plate:- 2-fold serial dilutions of antibodies (note that the complement in polyclonal
antisera was first inactivated by incubation of sera at 56°C); 10 μl of a 1:2500 dilution of the
bacterial cell suspension (expected to contain ~104 CFU); the exogenous complement source
(i.e. pooled human serum) and assay buffer to a total volume of 50 μl. Three control assays
were setup on each plate to assess: antibody-independent serum sensitivity to exogenous com-
plement (cells plus complement only), complement-independent killing by antibodies (cells
plus antibodies and heat-inactivated complement) and the fitness of cells used in the assay
(duplicate wells containing cells plus heat-inactivated complement, one of which was plated
prior to incubation to obtain a T0 count). Plates were subsequently incubated at 37°C for
1 hour. Samples from all assay wells were plated at the end of the experiment to provide T60
counts.
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Results
Construction of meningococcal strains lacking haemoglobin and
transferrin receptors
In order to investigate the contributions of the haemoglobin binding proteins of N.meningiti-
dis to the ability of meningococci to cause invasive disease, parts of the hmbR and hpuAB loci
were deleted and replaced by antibiotic cassettes. Mutations were constructed in a strain with
only the HmbR receptor, strain MC58, and one, strain 8047, with both receptors (i.e. HmbR
and HpuAB). The tbpBA genes were also inactivated by a similar method in both wild-type
(wt) and hmbRmutant backgrounds. The repeat tracts of the Hb receptors in the wt strains
and tbpBAmutants were sequenced, HmbR was in the ON state in the MC58 strain-back-
ground but OFF in strain 8047 wherein HpuAB was in an ON state. Growth assays showed
similar doubling times for the wt and mutant strains in MH broth (data not shown). Pheno-
typic characterisation of wt and mutant MC58 strains was then performed using a disc diffu-
sion assay. The MC58ΔhmbR utilized Tf but not Hb whilst the converse was observed for
MC58ΔtbpBA (Fig 1A). The MC58 double mutant was unable to utilize Tf or Hb whilst the wt
strain utilised both (Fig 1A). Similarly, only the 8047ΔhmbRΔhpuABmutant was unable to uti-
lise Hb while all 8047ΔtbpBAmutants failed to grow when Tf was the sole iron source (Fig 1B).
The ability of ΔhpuABmutants to utilise Hb could be due to the presence of small numbers of
hmbR-ON phase variants in the inoculum. All strains utilized free iron provided in the form of
Fig 1. Utilization of Hb and Tf by wild-type andmutantN.meningitidis strains.Desferal (40 μg/ml) was added to molten MH agar to chelate available
iron in the agar. A suspension of 108 cells from an overnight culture was spread onto each plate before sterile filter discs infused with either 100 μg of Hb or
500 μg of Tf were placed on the agar. Plates were incubated at 37°C, 5% CO2 for 24 hours. Discs infused with FeCl3 and PBS were used as positive and
negative controls. Panel (A) MC58; panel (B) 8047.
doi:10.1371/journal.pone.0133855.g001
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0.1 M FeCl3 (Fig 1). The hemO gene is located upstream of the hmbR gene and HemO is
required for utilisation of haem derived from Hb [45]. All mutant strains are assumed to have
retained HemO function as indicated by the ability of 8047ΔhmbR to grow on Hb presumably
through the combined actions of HpuAB and HemO.
Absence of HmbR does not impair growth of meningococci in human
whole blood
Sensitivity of Nm to the bactericidal activity of whole blood has been shown previously [41,
42]. Use of donors (V1 and V2) deficient in the mannose-binding ligand (MBL, a known acti-
vator of complement-mediated killing of meningococci) and growth of strains with an exoge-
nous sialylation source prior to inoculation into the blood was pursued in order to increase
bacterial survival. Despite these precautions, both wt and mutant 8047 strains were not recov-
erable from blood after 60 minutes (data not shown). Addition of either 5 mM or 10 mM
EDTA to inactivate the complement system in either an MBL-deficient (V1) or normal donor
(V3), in addition to exogenous sialylation, did not result in a reduction of the bactericidal
activity of whole blood to strain 8047 (Fig 2A). The susceptibility of strain 8047 to 20% human
serum (individually tested against serum from two separate donors) but not 5% serum suggests
that killing of strain 8047 in whole blood was complement-mediated (data not shown). Hence,
the impact of the absence of hpuAB on growth in the human whole blood model was unattain-
able in this study.
Decreases in CFU counts were observed immediately after inoculation of whole blood with
strain MC58 but with a much higher level of killing in blood from the V2 as compared to the
V1 donor (Fig 2B and 2C). For both donors, the ΔtbpBAmutants were less sensitive to the bac-
tericidal activity of the blood than the wt or HmbR knock-out mutant. Following these initial
reductions in CFU, both MC58 wt and MC58ΔhmbR grew exponentially from T60 to T480 in
blood from both donors with average doubling times of 49 and 36 minutes, respectively. Both
ΔtbpBAmutants exhibited a lower growth rate in both V1 and V2 blood with average doubling
times of 80 (MC58ΔtbpBA) and 93 (MC58ΔhmbRΔtbpBA) minutes. Growth of the single and
double ΔtbpBA knockout strains in human whole blood was significantly different to those
obtained in MH broth, as doubling times of 45 (MC58ΔtbpBA) and 48 (MC58ΔhmbRΔtbpBA)
minutes were recorded (one-tailed paired t-test; p = 0.04) whereas the wt and ΔhmbR strains
exhibited similar growth rates in blood and MH broth (p = 0.29).
Anti-HpuA and anti-HmbR antibodies recognise surface-exposed
variant-specific epitopes
The antigenic diversities of hpuAB and hmbR are mainly due to the presence of variable
regions (VR), which encode surface-exposed immunodominant loops [28, 31]. The degree of
cross-reactivity between meningococcal strains expressing different antigenic types of these
receptors was examined using polyclonal antisera raised against recombinant proteins purified
from E. coli extracts. Mouse sera containing anti-r8047-HpuA, anti-rN88-HpuA and anti-
r8047-HpuB antibodies were used to probe iron-starved cells of strain 8047, 8047 ΔhpuAB
mutant (8047ΔhpuAB), N88.1 (hpuAB-OFF) and N272.1 (hpuAB-ON) by Western blotting,
flow cytometry and colony immunoblotting assays. The N88.1 and N272.1 isolates were
sequentially isolated from the same healthy volunteer [2] and were shown to be hpuAB phase
variants of the same strain (Y:P1.21,16:F3-7:CC-174); [46]).
Both anti-rHpuA mouse antisera bound to a protein of the expected size (~40-kDa) in
Western blots of meningococcal lysates of strain 8047 and CC174 hpuAB-ON variant (N272.1)
but not the 8047ΔhpuABmutant or the CC174 hpuAB-OFF variant (N88.1), indicating specific
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Fig 2. Growth of Hb and Tf receptor mutants of N.meningitidis in whole human blood. Bacterial strains
(8047, MC58 and mutants thereof) were grown to mid-log (OD600 = ~ 0.6) in MHB supplemented with 20 μM
CMP-NANA and then added to freshly-collected human blood. Cultures were incubated at 37°C, 5% CO2 for
4 hours. Samples, collected from the inoculum and at 0, 60, 120, 180 and 240 minutes from blood cultures,
were plated in duplicate onto supplemented BHI agar. The Fig shows a representative experiment. Each
strain and mutant was tested in triplicate and intra-assay variation was measured by calculating the standard
error of the mean of the CFU counts obtained at each timepoint. Blood samples were collected from two
healthy MBL-deficient volunteers (V1 and V2) and an uncharacterised volunteer (V3). (A) strain 8047 (wt) in
blood from V2 and V3, which was treated with either 5 mM or 10 mM EDTA; (B) wild-type and mutants of
strain MC58 in untreated blood from V1; (C) wild-type and mutants of strain MC58 in untreated blood from V2.
doi:10.1371/journal.pone.0133855.g002
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reactivity with HpuA (Fig 3). Surface expression of HpuA in the 8047 and N272.1 strains
was demonstrated by detection of high reactivity to formalin-fixed cells in the FACs assays
(Fig 4A and 4B). No difference was observed, by Western blotting or FACs, in binding of anti-
r8047-HpuA antibodies to strains N272.1 and 8047 whereas the anti-rN88-HpuA sera exhib-
ited a major reduction in reactivity with 8047-HpuA as compared to N88.1-HpuA. This sug-
gests that there are either differences in the level of HpuA expression, with a lower level of
expression in strain 8047 as compared to the CC174 strain, or differences in the amounts of
variant specific antibodies in each serum (i.e. more variant-specific antibodies in the N88 ver-
sus the 8047 sera). Further testing of the reactivity of anti-HpuA antisera to a panel of carriage
strains in colony immunoblots showed specific reactivity of anti-rN88-HpuA to only the cog-
nate CC-174 strains, N46 and N52 (Fig 4E). These CC-174 isolates were isolated from the same
hall of residence and represent a cluster of genotypically identical strains that are thought to be
a product of clonal expansion within the hall of residence [2]. A very weak interaction between
anti-r8047-HpuA antibodies and the CC-174 strains was observed but no reactivity with other
strains in the panel could be discerned (Fig 4D).
Fig 3. Reactivity of anti-rHpuA and anti-rHpuB antisera with HpuAB in meningococcal lysates.Meningococcal cells of strain 8047, an isogenic Δhpu
mutant and two phase variants of a carriage strain (N88.1, hpu-OFF; and N272.1, hpu-ON) were grown to mid-log (OD600 = ~0.5) before 30 μM of desferal
was added to produce iron-limited conditions. Cultures were also grown concurrently in iron-replete conditions. All cultures were incubated for two hours
before heat-inactivation at 56°C overnight. Lysates were prepared using an equal number of OD units and subject to SDS-PAGE electrophoresis and
Western blotting. Blots were then probed with 1:500 dilutions of mouse polyclonal sera followed by a 1:2000 dilution of an anti-mouse IgG HRP-conjugate:-
upper panel, anti-rN88-HpuA; middle panel, anti-r8047-HpuA; lower panel anti-r8047-HpuB. Lysates were from:- strain N88.1, induced (lane 1);
8047ΔhpuAB, induced (lane 2); wild-type 8047, uninduced (lane 3); wild-type 8047, induced (lane 4); N272.1 uninduced (lane 5); and N272.1 induced (lane
6).
doi:10.1371/journal.pone.0133855.g003
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No discernible reactivity by anti-r8047-HpuB to surface-exposed HpuB regions in any of
the four strains analysed was observed (Fig 4C) whereas the Western blots showed clear and
specific reactivity with HpuB in whole cell lysates (Fig 3). The absence of reactivity between
anti-rHpuB antibodies and surface-expressed HpuB could be due to a lack of accessibility due
to blocking by HpuA, conformational changes to HpuB occurring during formation of a recep-
tor complex with HpuA [21] or improper folding of HpuB during preparation of recombinant
protein.
The reactivity of anti-r8047-HmbR and anti-rMC58-HmbR polyclonal antisera to Nm was
assessed by probing lysates (Fig 5) and formalin-fixed cells (Fig 6) of strains 8047 (hmbR-OFF),
H44/76 and MC58 (both hmbR-ON but antigenically dissimilar) or an MC58ΔhmbR. Both
polyclonal antisera bound to a protein of ~90-kDa in iron-induced MC58 and H44/76 cells but
not to MC58ΔhmbR, 8047 or uninduced cells. The anti-rMC58-HmbR serum showed cross-
reactivity with a protein of a slightly larger size accounting for the reactivity with strain 8047,
which is HmbR OFF. Consistent results were obtained using colony immunoblots (Fig 6D and
6E). In flow cytometry assays (Fig 6A and 6B), however, the polyclonal sera only showed reac-
tivity to induced cells of strain MC58 and not to H44/76, indicating that epitopes detected in
the Western and colony-immuno blots with this strain were not surface-exposed. A low degree
of reactivity to iron-starved 8047 cells was observed with the homologous anti-r8047-HmbR
Fig 4. Evaluation of HpuA and HpuB surface expression by flow cytometry and immunoblotting.Cultures of meningococcal strains 8047ΔhpuAB,
8047 wild-type, N88.1 and N27.12 were subjected to growth in iron-limited conditions (see Fig 3). Formalin-fixed cells were assessed for surface expression
of HpuA or HpuB in a FACS assay (panels A-C) by incubation with a 1:20 dilution of a polyclonal mice antiserum followed by a 1:100 dilution of a secondary
antibody (Alexa Fluor anti-Mouse IgG) and detection of fluorescence in a flow cytometer. A total of 25,000 events were analysed for each assay. Primary
antisera were:- (A) anti-r8047-HpuA; (B) anti-rN88-HpuA; (C) anti-r8047-HpuB. Strain are as indicated in the key. Immunoblotting (panels D-E) was
performed using meningococcal cells grown on supplemented BHI agar containing 65 μM desferal and incubated at 37°C, 5% CO2. Cells were transferred to
nitrocellulose filters and probed with a 1:250 dilution of either an anti-r8047-HpuA (D) or an anti-rN88-HpuA (E) followed by a 1:2000 dilution of an anti-Mouse
IgG AP-conjugate.
doi:10.1371/journal.pone.0133855.g004
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Fig 6. Evaluation of HmbR surface expression by flow cytometry and colony immunoblotting. Cultures of meningococcal strains were subjected to
growth in iron-limited or iron-replete conditions as described in Fig 3. Formalin-fixed cells were subsequently assessed for HmbR surface expression in a
FACS assay using a 1:20 dilution of a primary antibody followed by a 1:100 dilution of a secondary antibody (Alexa Fluor anti-Mouse IgG) and detection of
fluorescence in a flow cytometer. Primary antibodies were:- (A) a polyclonal anti-r8047-HmbR antiserum; (B) a polyclonal anti-rMC58-HmbR antiserum; and
(C) L11, an anti-HmbRmonoclonal antibody directed against surface-exposed loop 11. Strains were:- MC58ΔhmbR, purple line; MC58, blue line; 8047,
green line; and H44/76, red line. Colony immunoblots were also performed using meningococcal cells grown overnight on supplemented BHI agar with
65 μM desferal at 37°C, 5% CO2. Cells were transferred to nitrocellulose filters and probed with a 1:100 dilution of either a polyclonal anti-HmbR antiserum
(D) or a polyclonal serum raised against carrier proteins containing surface-exposed loops L2, L8 and L11 (E). The secondary antibody was an anti-mouse
IgG HRP-conjugate, which was used at a 1:2000 dilution.
doi:10.1371/journal.pone.0133855.g006
Fig 5. Reactivity of anti-HmbRmonoclonal and polyclonal antisera with HmbR in meningococcal lysates.Meningococcal lysates were prepared from
cells grown in iron-limited (induced) or iron-replete (uninduced) conditions as described for Fig 3. Equal amounts of cells were analysed by probing Western
blots with a 1:500 dilution of a primary antiserum followed by a 1:2000 dilution of an anti-Mouse IgG HRP conjugate. Upper panel, anti-r8047-HmbR; middle
panel, anti-rMC58-HmbR; lower panel, pooled mAbs raised against two surface exposed epitopes of the MC58 HmbR protein. Lysates were:- induced strain
MC58ΔhmbR (lane 1); uninduced wild-type MC58 (lane 2); induced wild-type MC58 (lane 3); uninduced wild-type 8047 (lane 4); induced wild-type 8047 (lane
5); uninduced wildtype H44/76 (lane 6); induced wildtype H44/76 (lane 7). Arrows, HmbR; asterisk, non-specific reactive protein.
doi:10.1371/journal.pone.0133855.g005
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antibody, possibly due to the presence of small numbers of hmbR-ON phase variants in the
population (Fig 6A). In addition to tight binding to MC58 cells, the anti-rMC58-HmbR serum
was reactive with carriage strains belonging to three different clonal complexes (N66.1, CC41/
44; N182.1, CC32; and N193.1, ST-845). Interestingly, no reactivity to strain N176.1, which is
antigenically homologous to MC58 with respect to hmbR, was found (Fig 6D). Sequence analy-
sis of the N176.1-hmbR gene revealed a premature stop codon, which was responsible for the
non-expression of hmbR and the consequent lack of a discernible interaction between the anti-
rMC58-HmbR serum and N176.1 cells.
Generation of monoclonal HmbR antibodies
Expression of surface-exposed loops in a heterologous carrier protein was explored as an alter-
native strategy for generation of bactericidal antibodies against HmbR. Using the structural
predictions contained in Evans et al. [28] for HmbR from strain MC58, the three largest sur-
face-exposed loops (L2, L8 and L11) were selected with L2 also being one of the loops exhibit-
ing the highest strain-to-strain variability and, therefore, presumed to be a major target of
antibody responses. These three surface loops of HmbR (see Materials and Methods) were
cloned from strain MC58 and inserted into EspA, an E. coli fimbrial protein. Polyclonal anti-
sera were raised in mice against mixtures of these recombinant proteins and three hybridomas
producing monoclonal antibodies specific for the hmbR loops were successfully cloned from
this serum. Two of the mAbs targeted loop 11 of hmbR and the third recognised loop 2. All
three mAbs bound to HmbR in meningococcal cell lysates of strain MC58 (Fig 5) but showed
no reactivity to surface-expressed HmbR by flow cytometry or colony immunoblotting (Fig 6C
and data not shown). Conversely, a polyclonal antiserum containing antibodies to all three
HmbR-EspA fusion proteins was highly reactive with surface-expressed HmbR in colony
immunoblots and specifically recognised HmbR in cell lysates (Figs 5 and 6). The poor binding
of mAbs to surface-expressed HmbR may be due to a combination of low concentrations of
antibodies and small amounts of surface-expressed HmbR.
Anti-rHpuA and anti-rHmbR antibodies are not bactericidal
An assessment of the bactericidal properties of antibodies targeting surface-expressed HpuA
and HmbR was performed with iron-starved Nm cells as both proteins are induced under low
iron conditions. This approach was previously employed during testing of the vaccine candi-
dacy of TbpA and TbpB [47–49]. Active human complement was derived from volunteers
whose sera had low levels of bactericidal activity against Nm [40].
For the anti-HpuA hSBAs, a 5% human serum extract was used due to the high sensitivity
of strain 8047 to human serum. The anti-r8047-HpuA serum exhibited no bactericidal activity
against either strain 8047 wt and 8047ΔhpuAB (Fig 7A). Contrastingly, a P1.2 mAb specific for
VR2 of PorA exhibited high levels of bactericidal activity for both strains with a titre of 640
(Fig 7B). The bactericidal activity of monoclonal and polyclonal anti-HmbR antibodies was
performed using strain MC58, mutants thereof and 20% serum. Bactericidal activity was
observed with an anti-PorA P1.7 mAb (hSBA titre of 320) but not with pooled anti-HmbR
mAbs or anti-rMC58-HmbR antisera (Fig 8).
Discussion
Hb is one of the most abundant sources of iron in the blood leading to the suggestion that hae-
moglobin utilisation is crucial for proliferation of blood-borne pathogens during systemic
spread [10]. During meningococcal disease, Hb may be a particularly important iron source as
the amount of iron-bound Tf molecules can be significantly reduced due to induction of a
Vaccine Candidacy of the Meningococcal Haemoglobin Receptors
PLOS ONE | DOI:10.1371/journal.pone.0133855 July 24, 2015 15 / 22
hypoferraimic response. Stojiljkovic et al. [29] showed that inactivation of hmbR in an hpuAB-
negative meningococcal strain was incapable of Hb utilisation and was less virulent than the
wild-type hmbR-positive strain in a rat infection model. Later genetic epidemiology studies
revealed a bias towards the presence of hmbR and a high level of PV-ON states (70–95%) for
one or both of the phase-variable Hb receptors in meningococcal disease isolates [27, 31, 32].
Fig 7. Testing the serum bactericidal activity of anti-rHpuA antisera.Meningococcal cell suspensions were prepared following growth under iron-
restricted conditions. An aliquot of 104 cfu was mixed with pooled human complement at a final concentration of 5% and dilutions (as indicated on the x-axis)
of either a polyclonal anti-rHpuA antiserum (A) or anti-PorA monoclonal antibody P1.2 (B). Assays were incubated at 37°C for 60 minutes and then assessed
for the numbers of surviving cells (cfu/ml) by plating 10μl of aliquots on supplmented BHI agar. Inoc, cell count after 0 minutes; No Ab, cell count after 60
minutes incubation in serum alone. Graphs showmean values for two independent experiments. Red line, 8047; blue line, 8047ΔhpuAB.
doi:10.1371/journal.pone.0133855.g007
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Fig 8. Testing the serum bactericidal assay of anti-HmbR antisera.Meningococcal cell suspensions,
grown in iron-replete (uninduced) and iron-deficient (induced) conditions, and assays were performed as
described for Fig 7. Antisera/antibodies were tested at the indicated dilutions for each sera against the
indicated strains:- (A) polyclonal anti-rHmbR antisera, blue line, uninduced MC58, red line induced MC58; (B)
pooled anti-HmbRmAbs, blue line induced MC58, red line induced MC58ΔHmbR; (C) a PorA monoclonal
antibody, P1.7, blue line induced MC58, red line induced MC58ΔHmbR. Inoc, cell count after 0 minutes; No
Ab, cell count after 60 minutes incubation in serum alone. Graphs showmean values for two independent
experiments for the pooled anti-rHmbR antisera and one for the PorA P1.7 and anti-HmbRmAbs.
doi:10.1371/journal.pone.0133855.g008
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The exact nature of the involvement of the phase-variable Hb receptors in meningococcal
virulence was examined using an ex vivo human whole blood model. Using a similar mutant to
Stojiljkovic et al. [29], we observed that loss of the capacity to utilise Hb, via inactivation of
hmbR in an hpuAB-negative strain (MC58), did not affect growth in human whole blood.
Contrastingly, growth of a ΔtbpBAmutant was impaired in human whole blood. Our results
support a critical role for TbpBA in infection as established by Zarantonelli et al. [50] who
observed a drastic reduction in survival of a meningococcal tbpBmutant as compared to the
parental strain during systemic infections of transgenic mice expressing human Tf. The dispar-
ity between our results and those of Stojiljkovic et al. [29] may be due to the meningococcal
TbpBA preferentially binding human Tf [51, 52]. Thus the MC58ΔhmbRmutant may not
grow in the rat model due to an inability to utilise rat Tf but can grow in human whole blood
by utilizing human Tf.
The lack of a role for HmbR during growth of meningococci in human blood is also surpris-
ing as Harrison et al. [31] detected a higher prevalence of the hmbR gene in meningococcal
disease isolates than carriage isolates. The concentration of free Hb in blood is estimated at
between 20–200 μg/ml depending on method of analysis and donor [53, 54]. Utilisation of free
Hb by meningococci was tested with 100 μg in our assays, which is towards the upper bound of
these estimates for free Hb in blood, and so it is possible that strain MC58 may not have grown
in healthy human blood from these donors because the level of free Hb was too low. However,
Zhao et al. [55] noted growth of wild-type meningococcal strains on 30–50 μg/ml free Hb and
so it is not clear if the availability of free Hb was a determinant of the inability of tbpmutants
to replicate in whole blood, The discrepancy may arise from the fact that the whole blood
model only mimics the early stages of an infection where iron-loaded Tf is abundant [56, 57].
Thus the TbpBA receptor may be sufficient for growth of meningococci during the early stages
of disease. However a decrease in Tf levels is anticipated over time during an infection and may
occur concomitantly with an increase in intravascular coagulation and erythrocyte lysis [58,
59]. Lysis of the erythrocytes may release Hb in quantities that exceed the sequestration capac-
ity (0.07–0.15 g/dL) of circulating Hp molecules [60] so that free Hb levels remain high. The
potential importance of release of Hb was shown by Adamzik et al. who observed higher levels
of free Hb in non-survivors as compared to survivors of sepsis [54]. Thus, an important role
for HmbR may only become apparent following the removal of Tf and induction of erythrocyte
lysis.
The presence of variable regions in the surface-exposed components of the Hb receptors
indicates that immune responses against these receptors exert a strong selection for antigenic
variation [28, 61]. Both receptors were immunogenic in mice and elicited antibodies that
bound to surface-exposed regions of the proteins in whole cells as detected by FACs. These
antibodies were not however bactericidal. The absence of bactericidal activity with the anti-
HmbR mAbs was likely due to low levels of antibodies in the hybridoma supernatants whilst
the inability of the anti-rHpuA and anti-rHmbR polyclonal antisera to mediate killing could
be a consequence of the relatively low levels of the target surface-exposed epitopes. The impor-
tance of the amount of surface expression for discernible bactericidal activity was iterated
by Giuntini et al. [62] who reported that from 4- to>10-fold higher amounts of anti-fHbp
antibodies were required to elicit bacteriolysis of wild-type cells compared to a fHbp over-
expression mutant. An inability of antibodies to mediate killing in an SBA, however, does not
necessarily translate into an inability to provide protection against meningococci. West et al.
[49] reported an incongruity between results obtained from SBAs and passive protection assays
in mice. Antibodies produced in mice using an rTbpA immunogen were non-bactericidal in
SBAs but the same rTbpA antigen, when used as a vaccine, protected mice from meningococcal
infection. Against this backdrop, the anti-rHpuA and anti-rHmbR antisera may still limit
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meningococcal infection via promotion of opsonophagocytosis, which has been described for a
non-bactericidal IgG3 antibody preparation induced in recipients of the Norwegian serogroup
B meningococcal vaccine [63], or via the inhibition of Hb utilisation by preventing interactions
between the Hb receptors and Hb or Hb complexes.
In summary, this study reports that the TbpBA receptor but not HmbR is required for
meningococci to replicate in human blood. This finding suggests that TbpBA and HpuAB may
be the main mediators of iron acquisition by meningococci during the early stages of an infec-
tion, due to the availability of apo-Tf and Hb-Hp complexes, whilst significant erythrocyte lysis
may be required before HmbR contributes to the disease process. This study also finds that
anti-rHpuA and anti-rHmbR antibodies are not bactericidal indicating that the meningococcal
Hb receptors are not viable vaccine candidates.
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